Pharmaceutical

TriSalus merges with MedTech Acquisition to bolster cash reserves

TriSalus is breaking into cancer therapeutics research with its TLR agonist SD-101 for treating solid tumours.

Aug 12, 2023 - 20:00
TriSalus merges with MedTech Acquisition to bolster cash reserves
TriSalus is breaking into cancer therapeutics research with its TLR agonist SD-101 for treating solid tumours.
Read the original article

Tags:

Previous Article

Genprex’s Reqorsa gene therapy picks up orphan drug designation from FDA for SCLC

Next Article

Oxurion unlocks $1m from Atlas for diabetic macular oedema therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Cold chain storage and distribution for the pharmaceutical industry

Cold chain storage and distribution for the pharmaceuti...

May 21, 2024

STAT+: European regulators endorse Casgevy, paving way for approval of CRISPR-based therapy

STAT+: European regulators endorse Casgevy, paving way ...

Dec 15, 2023

Pharma readies for climate disasters amidst supply chain concerns

Pharma readies for climate disasters amidst supply chai...

Dec 14, 2023